尼可地尔联合单硝酸异山梨酯缓释胶囊治疗不稳定型心绞痛临床疗效观察

目的 探讨尼可地尔片联合单硝酸异山梨酯缓释胶囊治疗不稳定型心绞痛（UAP）的临床疗效。方法 入住本院的UAP患者76例，随机分为观察组（ n ＝38）和对照组（ n ＝38）。所有患者均接受常规治疗，包括口服阿司匹林、酒石酸美托洛尔片、培哚普利、阿托伐他汀钙片等，对照组在常规治疗基础上加用单硝酸异山梨酯缓释胶囊．观察组患者在对照组基础上再联合使用尼可地尔片，治疗1个月后，观察两组临床疗效、动态心电图变化及不良反应发生率。结果 观察组治疗后的总有效率为94．7％，对照组为78．9％，两组比较有显著性差异（P ＜0．05）；观察组心电图改善情况优于对照组，差异有统计学意义（P ＜0．05）；治疗期间观察组出现轻微头痛1例（2．6％），对照组出现轻微头痛3例（7．89％），差异无统计学意义（P＞0．05）。治疗期间两组患者均无明显低血压和肝肾损害。结论 尼可地尔联合单硝酸异山梨酯可以显著改善 UAP患者的临床症状和心电图，近期疗效较好，且使用安全。

Observation on Clinical Efficacy of Nicorandil Combined with Isosorbide Mononitrate for the Treatment of Unstable Angina

Objective] To explore clinical efficacy of nicorandil combined with isosorbide mononitrate for the treatment of unstable angina（UAP） .Methods] A total of 76 patients with UAP in our hospital were ran‐domly divided into observation group（ n =38） and control group（ n =38） .All patients received conventional therapy including oral aspirin ,metoprolol tartrate tablets ,perindopril ,atorvastatin calcium tablets and so on . Moreover ,the control group received isosorbide mononitrate ,while the observation group was given nicorandil and isosorbide mononitrate based on the conventional therapy .Clinical efficacy ,dynamic electrocardiogram （ECG） changes and incidence of adverse reactions of 2 groups were observed .Results] Total effective rate of observation group and control group was 94 .7% and 73 .7% respectively ,and there was significant difference between two groups（ P 〈 0 .05） .The improvement of ECG in observation group was higher than that in con‐trol group ,and there was significant difference（ P 〉0 .05） .During the treatment ,light headache was found in 1 patient of observation group（2 .6% ） and 3 patients of control group（7 .89% ） ,but there was no significant difference（ P 〉 0 .05） .During the treatment ,no obvious hypoglycemia and liver damage was found in two groups .Conclusion]Nicorandil combined with isosorbide mononitrate for the treatment of patients with UAP is able to improve clinical symptoms and ECG ,and has good short‐term efficacy and safety .